Dechra Pharmaceuticals

Dechra is an international specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide. Our key focus therapeutic areas are: • Endocrinology • Dermatology • Anaesthesia and analgesia • Ophthalmology • Cardiovascular disease • Equine locomotion • Food producing animal antimicrobials • And pet diets
Lostock Gralam, GB
Size (employees)
1,308 (est)+52%
Dechra Pharmaceuticals was founded in 1997 and is headquartered in Lostock Gralam, GB

Dechra Pharmaceuticals Office Locations

Dechra Pharmaceuticals has offices in Lostock Gralam, Hadnall, Skipton, Melbourne and in 6 other locations
Lostock Gralam, GB (HQ)
Cheshire Business Park Roundabout
Torino, IT
Via Agostino da Montefeltro
Barcelona, ES
202 Carrer de Balmes
Uldum, DK
9 Mekuvej
Leawood, US
525 7015 College Blvd
Melbourne, US
2571 W Eau Gallie Blvd
Show all (10)

Dechra Pharmaceuticals Data and Metrics

Dechra Pharmaceuticals Financial Metrics

Dechra Pharmaceuticals's revenue was reported to be £247.6 m in FY, 2016 which is a 22% increase from the previous period.

Revenue (FY, 2016)

247.6 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

132.4 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

12.5 m

Market capitalization (24-Jul-2017)

1.6 b

Closing share price (24-Jul-2017)


Cash (30-Jun-2016)

39.1 m
Dechra Pharmaceuticals's current market capitalization is £1.6 b.
GBPFY, 2013FY, 2014FY, 2015FY, 2016


189.2 m193.6 m203.5 m247.6 m

Revenue growth, %


Cost of goods sold

88.5 m85.9 m87.3 m115.1 m

Gross profit

100.7 m107.7 m116.1 m132.4 m

Gross profit Margin, %


Operating expense total

82.4 m82.7 m90.2 m112.9 m

Pre tax profit

21.4 m25.8 m14.5 m

Net Income

19.4 m19.5 m12.5 m
GBPFY, 2014FY, 2015FY, 2016


26.8 m45.9 m39.1 m

Accounts Receivable

28.3 m27.7 m59.2 m

Current Assets

86.3 m108.6 m162.5 m


18.3 m18.2 m37.9 m


196.2 m166.7 m360.4 m

Total Assets

300.8 m293.5 m560.8 m

Accounts Payable

12.9 m10.4 m24.3 m

Current Liabilities

35.7 m44.1 m66.3 m

Total Liabilities

96 m99 m286.1 m

Retained Earnings

6.8 m5.6 m(2.6 m)

Total Equity

204.8 m194.5 m274.6 m

Financial Leverage

1.5 x1.5 x2 x
GBPFY, 2014FY, 2015FY, 2016

Cash From Operating Activities

11.5 m41 m43.6 m

Cash From Financing Activities

(92.1 m)(14.8 m)125.3 m

Income Taxes Paid

(2 m)(6.3 m)(2 m)
GBPY, 2016


286.9 k

Financial Leverage

2 x

Dechra Pharmaceuticals Market Value History

Dechra Pharmaceuticals Job Categories

Traffic Overview of Dechra Pharmaceuticals

Dechra Pharmaceuticals Online and Social Media Presence

Dechra Pharmaceuticals News and Updates

Merlin's share price loses its magic despite revenues rising

Merlin Entertainment's share price dipped today despite the world's second largest tourist attraction operator posting a rise in revenue. The figures Revenue at the Thorpe Park and Alton Towers operator grew 5.3 per cent to £573m in the 26 weeks ended 25 June, up from £544m in the same period …

Dechra Pharmaceuticals Company Life and Culture

You may also be interested in